Dag Trader schreef op 13 september 2019 08:48:
op de CAT agenda...
2.6. Update on ongoing initial applications
2.6.1. Viable T-cells - Orphan - EMEA/H/C/002397
Kiadis Pharma Netherlands B.V.; adjunctive treatment in haematopoietic stem cell
transplantation (HSCT) for a malignant disease
Scope: feedback from the ad-hoc expert group meeting that took place on 3 September
Committee for Advanced Therapies (CAT)
EMA/CAT/501754/20192019 Page 6/19
2019.
Action: for information
www.ema.europa.eu/en/documents/agenda...